41 – 50 of 63
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: Implications for multiple myeloma
(
- Contribution to journal › Article
-
Mark
The role of RANK-ligand inhibition in cancer : the story of denosumab
(
- Contribution to journal › Scientific review
- 2010
-
Mark
Multiparametric Flow Cytometry Profiling of Neoplastic Plasma Cells in Multiple Myeloma
(
- Contribution to journal › Article
-
Mark
The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo
(
- Contribution to journal › Article
- 2009
-
Mark
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies
(
- Contribution to journal › Scientific review
-
Mark
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study
(
- Contribution to journal › Article
- 2008
-
Mark
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
(
- Contribution to journal › Article
- 2007
-
Mark
An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
(
- Contribution to journal › Article
- 2006
-
Mark
Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells
(
- Contribution to journal › Article